Section Arrow
NGNE.NASDAQ
- Neurogene
Quotes are at least 15-min delayed:2025/07/21 06:42 EDT
Pre Market
Last
 --
-- (--)
Bid
18.54
Ask
23.88
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 22.34
-0.26 (-1.15%)
Day High 
23.5 
Prev. Close
22.6 
1-M High
23.27 
Volume 
111.11K 
Bid
18.54
Ask
23.88
Day Low
22.31 
Open
23 
1-M Low
14.65 
Market Cap 
322.32M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 21.34 
20-SMA 19.37 
50-SMA 18.72 
52-W High 74.49 
52-W Low 6.875 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.36/-4.52
Enterprise Value
332.47M
Balance Sheet
Book Value Per Share
20.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
925.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.13 -0.945 -6.71%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:42 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.